Edge Rewrite
// HTMLRewriter · presentation

This page was redesigned at the edge.

Cloudflare fetched the original article and streamed it through HTMLRewriter to apply an entirely new visual system without rebuilding the source page.

Jump to content

Gareth Sanger

From Wikipedia, the free encyclopedia

Gareth Sanger
Employers
Websitewww.icms.qmul.ac.uk/neurogastro/staff/garethsanger.html Edit this at Wikidata

Gareth J. Sanger (born 1953) is a British pharmacologist.

Sanger was a research fellow at King's College Hospital Medical School from 1977 to 1990.[1] He then spent a period in the pharmacological industry,[1] before being appointed, in 2009, Professor of Neuropharmacology, at Queen Mary University of London.[2]

He has served as editor and reviews editor for the "British Journal of Pharmacology" and as an editorial board member for "Drug Discovery Today".[1]

Together with M Tyers he received the 1998 Pharmaceutical Research and Manufacturers of America (PhRMA) "Discoverer's Award" for their research into 5HT3 receptor/antiemesis, which led to the identification and development of the drug Kytril,[1][2] an antiemetic to treat nausea and vomiting following chemotherapy.

References

[edit]
  1. 1 2 3 4 Daphne Christie; Tilli Tansey, eds. (2007). The Discovery, Use and Impact of Platinum Salts as Chemotherapy Agents for Cancer. Wellcome Witnesses to Contemporary Medicine. History of Modern Biomedicine Research Group. ISBN 978-0-85484-112-7. OL 25554713M. Wikidata Q29581749.
  2. 1 2 "Gareth Sanger". The Conversation. Retrieved 26 June 2017.
[edit]